12-Jun-2026
Iovance Shareholders Approve Expanded Capital Flexibility and Governance
TipRanks (Wed, 10-Jun 6:40 PM ET)
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Globe Newswire (Mon, 8-Jun 9:01 AM ET)
Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Globe Newswire (Wed, 3-Jun 4:05 PM ET)
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
Globe Newswire (Mon, 1-Jun 8:30 AM ET)
Globe Newswire (Mon, 1-Jun 7:30 AM ET)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 22-May 5:15 PM ET)
Iovance Biotherapeutics to Present at Upcoming Conference
Globe Newswire (Thu, 21-May 8:05 AM ET)
Globe Newswire (Thu, 7-May 7:05 AM ET)
Globe Newswire (Mon, 27-Apr 8:01 AM ET)
Iovance Biotherapeutics Delivers 30% Quarterly Revenue Growth and Achieves Key Clinical Milestones
Market Chameleon (Wed, 25-Feb 6:17 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of June 12, 2026, IOVA stock price climbed to $4.08 with 10,481,859 million shares trading.
IOVA has a beta of 0.89, meaning it tends to be less sensitive to market movements. IOVA has a correlation of 0.01 to the broad based SPY ETF.
IOVA has a market cap of $1.82 billion. This is considered a Small Cap stock.
Last quarter Iovance Biotherapeutics reported $71 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.03.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a price return of +76.6% while the SPY ETF gained +24.1%. However, in the short term, IOVA had mixed performance relative to the market. It has underperformed in the last 3 months, returning +0.2% vs +11.6% return in SPY. But in the last 2 weeks, IOVA shares have fared better than the market returning -0.5% compared to SPY -1.9%.
IOVA support price is $3.73 and resistance is $4.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.